| Name | ethyl 4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazole-5-carboxylate |
|---|---|
| Synonyms |
ethyl 2-[[(tert-butyloxy)carbonyl]amino]-4-methyl-1,3-thiazole-5-carboxylate
2-tert-butoxycarbonylamino-4-methylthiazole-5-carboxylic acid ethyl ester ethyl-2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylate ethyl 2-tert-butoxycarbonylamino-4-methylthiazole-5-carboxylate ethyl 2-(tert-butoxycarbonylamino)-4-methylthiazole-5-carboxylate |
| Molecular Formula | C12H18N2O4S |
|---|---|
| Molecular Weight | 286.34700 |
| Exact Mass | 286.09900 |
| PSA | 109.25000 |
| LogP | 2.98880 |
| HS Code | 2934100090 |
|---|
|
~79%
244236-52-0 |
| Literature: NOVARTIS AG; XENON PHARMACEUTICALS INC. Patent: WO2009/103739 A1, 2009 ; Location in patent: Page/Page column 78-79 ; WO 2009/103739 A1 |
|
~%
244236-52-0 |
| Literature: Kim, Hwa-Ok; Kahn, Michael Synlett, 1999 , # 8 p. 1239 - 1240 |
| Precursor 3 | |
|---|---|
| DownStream 1 | |
| HS Code | 2934100090 |
|---|---|
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |